AdvaMed and two other industry groups continue to press Congress to repeal the 2.3% medical device tax as the first payment due date has arrived. "This tax is already resulting in layoffs, reduced investments in R&D and delays in significant capital improvements. We urge Congress to act swiftly and repeal this job-killing, innovation destroying, anti-competitive tax," AdvaMed President and CEO Stephen Ubl said.

Related Summaries